Compare Crispr Therapeutics AG (CRSP) vs Dow Jones Industrial Average ETF (DIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Dow Jones Industrial Average ETF — how do they compare? Crispr Therapeutics AG trades at $53.65 (market cap $4.88B), while Dow Jones Industrial Average ETF trades at $515.8 (market cap $45.20B). The key difference: Dow Jones Industrial Average ETF is far larger — about 9.3× Crispr Therapeutics AG's market cap, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Dow Jones Industrial Average ETF for 103 Days on average.
| CRSP | DIA | |
|---|---|---|
Market Cap | $4.88B | $45.20B |
Volume | 2,861,747 | 4,095,368 |
Sector | Health | — |
52-Week High | $74.92 | $542.79 |
52-Week Low | $44.34 | $451.37 |
Typical Hold Time | 77 Days | 103 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
DIA trades at $513.34, showing modest 0.45% daily gains amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent dividend distributions provide income appeal, but key valuation metrics are unavailable for comprehensive fundamental assessment. Market sentiment reflects broader equity concerns as highlighted in recent financial coverage.
The outlook remains cautious given technical weakness and market volatility. Dividend payments offer income stability, but the absence of fundamental metrics limits valuation clarity. Key risks include broader market pressures and economic uncertainty, requiring careful monitoring of Dow Jones component performance for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →
